Overview

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release. There will be 6 scheduled clinic visits and 2 treatment groups.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids